Trial Profile
An Open-label, Multicenter, Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Non-resectable, Non-transplantable, Non-radiofrequency Ablation (RFA) Treatable Hepatocellular Carcinoma (HCC)
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs TBI 302 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; First in man
- Sponsors Therapure Biopharma
- 08 Apr 2015 New trial record